Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.46 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446602 | 0.90 | MAPT (0.50) | SLC22A12HSPB1ARALDH1A1LMNA | |
| SCHEMBL11779619 | 0.81 | HSPB1 (0.68) | SLC22A12HSPB1ARALDH1A1 | |
| SCHEMBL2445073 | 0.79 | PIN1 (0.47) | SLC22A12HSPB1 | |
| SCHEMBL8867069 | 0.79 | HSPB1 (0.57) | HSPB1ALDH1A1LMNAHPGDHTT | |
| SCHEMBL12216024 | 0.78 | AR (0.50) | SLC22A12AR | |
| SCHEMBL11100867 | 0.78 | AR (0.53) | SLC22A12AR | |
| SCHEMBL17407526 | 0.78 | AR (0.50) | SLC22A12AREPAS1 | |
| SCHEMBL4065173 | 0.77 | HSPB1 (0.55) | HSPB1ALDH1A1LMNAHPGDHTT | |
| SCHEMBL11089663 | 0.77 | SLC22A12 (0.40) | SLC22A12HSPB1ARLMNAHTT | |
| SCHEMBL16792430 | 0.76 | MAPT (0.53) | ARALDH1A1LMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981851-B1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| EP-1981851-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | MAP3K1, MAP3K19, MAP3K20 | SLC22A12 2930/4885HSPB1 2698/4885AR 3132/4885 |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | MAP3K19, MAP3K2, MAP3K20 | SLC22A12 2466/4885HSPB1 3923/4885AR 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.